Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Tonix Pharmaceuticals Holding (TNXP) Other Non Operating Income (2023 - 2026)

Tonix Pharmaceuticals Holding has reported Other Non Operating Income over the past 4 years, most recently at -$3000.0 for Q1 2026.

  • For Q1 2026, Other Non Operating Income rose 99.86% year-over-year to -$3000.0; the TTM value through Mar 2026 reached -$1.2 million, up 60.83%, while the annual FY2025 figure was -$2.1 million, 141.29% down from the prior year.
  • Other Non Operating Income for Q1 2026 was -$3000.0 at Tonix Pharmaceuticals Holding, up from -$1.2 million in the prior quarter.
  • Over five years, Other Non Operating Income peaked at $897000.0 in Q1 2023 and troughed at -$2.1 million in Q1 2025.
  • A 4-year average of -$332111.1 and a median of -$3000.0 in 2026 define the central range for Other Non Operating Income.
  • Biggest five-year swings in Other Non Operating Income: plummeted 12485.71% in 2024 and later surged 99.86% in 2026.
  • Year by year, Other Non Operating Income stood at $7000.0 in 2023, then plummeted by 12485.71% to -$867000.0 in 2024, then crashed by 33.33% to -$1.2 million in 2025, then surged by 99.74% to -$3000.0 in 2026.
  • Business Quant data shows Other Non Operating Income for TNXP at -$3000.0 in Q1 2026, -$1.2 million in Q3 2025, and -$2.1 million in Q1 2025.